4-氟苯并呋喃 | 24410-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 4-氟苯并呋喃
• 英文名称: 4-fluorobenzofuran-6,4g-formamide
• 英文别名: 4-fluorobenzofuran；4-fluoro-1-benzofuran
• CAS: 24410-58-0
• 化学式: C₈H₅FO
• mdl: MFCD10699416
• 分子量: 136.126
• InChiKey: NZUXZSQNFHYMCH-UHFFFAOYSA-N

物化性质

• 沸点：
  171.7±13.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氟苯并呋喃 在 盐酸 、 三乙基硅烷 、 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 正丁基锂 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， -78.0~100.0 ℃ 、379.22 kPa 条件下， 反应 0.33h， 生成 2-[4-[4-fluoro-5-(1-propylsulfonyl-3,6-dihydro-2H-pyridin-4-yl)-2,3-dihydro-1-benzofuran-2-yl]piperidin-1-yl]-5-propylpyrimidine
  参考文献：
  名称：

  Synthesis and structure–activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists

  摘要：

  Through appropriate medicinal chemistry design tactics and computer-assisted conformational modeling, the initial lead A was evolved into a series of dihydrobenzofuran derivatives 3 as potent GPR119 agonists. This Letter describes the optimization of general structure 3, including the substituent(s) on dihydrobenzofuran, the R-1 attachment on right-hand piperidine nitrogen, and the left-hand piperidine/piperazine and its attachment R-2. The efforts led to the identification of compounds 13c and 24 as potent human GPR119 modulators with favorable metabolic stability, ion channel activity, and PXR profiles. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.096
• 作为产物：
  描述：

  6-氟水杨醛 在 吡啶 、 氯化亚砜 、 potassium carbonate 、 cesium fluoride 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 4-氟苯并呋喃
  参考文献：
  名称：

  Synthesis and structure–activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists

  摘要：

  Through appropriate medicinal chemistry design tactics and computer-assisted conformational modeling, the initial lead A was evolved into a series of dihydrobenzofuran derivatives 3 as potent GPR119 agonists. This Letter describes the optimization of general structure 3, including the substituent(s) on dihydrobenzofuran, the R-1 attachment on right-hand piperidine nitrogen, and the left-hand piperidine/piperazine and its attachment R-2. The efforts led to the identification of compounds 13c and 24 as potent human GPR119 modulators with favorable metabolic stability, ion channel activity, and PXR profiles. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.096

文献信息

• POLYMERIZABLE MONOMER, POLYMER COMPOUND FOR CONDUCTIVE POLYMER, AND METHOD FOR PRODUCING THE POLYMER COMPOUND
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20200247926A1

  公开（公告）日：2020-08-06

  Polymerization reaction is performed using a polymerizable monomer shown by the following general formula (1) and at least one monomer selected from monomers each having a structure of a salt among a lithium salt, a sodium salt, a potassium salt, and a nitrogen compound salt of a fluorosulfonic acid or the like; then, the structure of the salt of the repeating unit of a polymer obtained by the polymerization reaction is changed to the fluorosulfonic acid or the like by ion exchange. Thus, the present invention provides a polymer compound for a conductive polymer and a method for producing the polymer compound which is suitably used as a dopant for a fuel cell and a conductive material, and which is a copolymer containing a repeating unit of styrene having a 3,3,3-trifluoro-2-hydroxy-2-trifluoromethylisobutyl ether group, and a repeating unit having any of a fluorosulfonic acid, a fluorosulfonimide group, and a n-carbonyl-fluoro-sulfonamide group.

  聚合反应使用以下一般式（1）所示的可聚合单体和至少一种选择自锂盐、钠盐、钾盐和氟磺酸盐等盐结构的单体中的单体进行；然后，通过离子交换将聚合反应得到的聚合物的重复单元的盐结构改变为氟磺酸盐或类似物。因此，本发明提供了一种用作导电聚合物的聚合物化合物以及用作燃料电池和导电材料的掺杂剂的聚合物化合物的生产方法，该聚合物是含有3,3,3-三氟-2-羟基-2-三氟甲基异丁基醚基的苯乙烯重复单元和具有氟磺酸、氟磺酰亚胺基团和n-羰基-氟磺酰胺基团中的任何一种的重复单元的共聚物。
• Purine derivatives as kinase inhibitors
  申请人：Engler Albert Thomas

  公开号：US20050090483A1

  公开（公告）日：2005-04-28

  The present invention provides kinase inhibitors of Formula I.

  本发明提供了式I的激酶抑制剂。
• Fluorinated aromatic compounds and the use of the same in liquid crystal mixtures
  申请人：——

  公开号：US20040124399A1

  公开（公告）日：2004-07-01

  The invention relates to fluorinated aromatics of the formula (I) 1 where X is CH 2 , C═O, CF 2 , O or S, Y is H or F, with the proviso that Y has to be F when X is CH 2 , and where the other parameters are as defined in claim 1, and also to their use in liquid-crystal mixtures, and also to liquid-crystal mixtures comprising these compounds and to liquid-crystal displays comprising these mixtures.

  本发明涉及式(I)的氟化芳香化合物1，其中X为CH2、C═O、CF2、O或S，Y为H或F，但当X为 时，Y必须为F。其他参数如权利要求1所定义，以及它们在液晶混合物中的使用，以及包含这些化合物的液晶混合物和包含这些混合物的液晶显示器。
• Composition containing carbon nanotubes having coating thereof and process for producing them
  申请人：Saitoh Takashi

  公开号：US20060052509A1

  公开（公告）日：2006-03-09

  The object of the present invention is to provide a carbon nanotube composition that does not impair the characteristics of the carbon nanotubes itself, allows the carbon nanotubes to be dispersed or solubilized in a solvent, does not cause separation or aggregation of the carbon nanotubes even during long-term storage, has superior electrical conductivity, film formability and moldability, can be easily coated or covered onto a base material, and the resulting coated film has superior moisture resistance, weather resistance and hardness; a composite having a coated film composed thereof; and, their production methods. In order to achieve this object, the present invention provides a carbon nanotube composition that contains a conducting polymer (a) or heterocyclic compound trimer (i), a solvent (b) and carbon nanotubes (c), and may additionally contain a high molecular weight compound (d), a basic compound (e), a surfactant (f), a silane coupling agent (g) and colloidal silica (h) as necessary; a composite having a coated film composed of the composition; and, their production methods.

  本发明的目的是提供一种碳纳米管组合物，不会影响碳纳米管本身的特性，使碳纳米管可以分散或溶解在溶剂中，在长期储存期间不会导致碳纳米管分离或聚集，具有优异的电导性、成膜性和成型性，可以轻松地涂覆或覆盖在基材上，所得到的涂层膜具有优异的防潮性、耐候性和硬度；一种由涂层膜组成的复合材料；以及它们的生产方法。为了实现这一目的，本发明提供了一种碳纳米管组合物，其中包含导电聚合物(a)或杂环化合物三聚体(i)、溶剂(b)和碳纳米管(c)，并可根据需要另外包含高分子量化合物(d)、碱性化合物(e)、表面活性剂(f)、硅烷偶联剂(g)和胶体二氧化硅(h)；一种由该组合物组成的涂层膜复合材料；以及它们的生产方法。
• N-aroyl cyclic amine derivatives as orexin receptor antagonists
  申请人：——

  公开号：US20040180887A1

  公开（公告）日：2004-09-16

  This invention relates to N-aroyl cyclic amine derivatives of formula (1), wherein X represents a bond, oxygen, NR 3 or a group (CH 2 ), wherein n represents 1, 2 or 3; Y represents CH 2 , CO, CH(OH), or CH 2 CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar 2 represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists. 1

  本发明涉及式（1）的N-芳基环状胺衍生物，其中X代表键，氧，NR3或(CH2)基团，n代表1、2或3; Y代表 、CO、CH(OH)或 CH(OH); Het是一个可选的含有最多4个N、O和S中的杂原子的双环杂芳基基团; Ar2代表一个可选的苯基或含有最多3个N、O和S中的杂原子的5-或6元杂环基团，并且它们作为药物使用，特别是作为觉醒素受体拮抗剂。